These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 29186087)

  • 1. Three more immune checkpoint inhibitors for advanced bladder cancer.
    Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
    [No Abstract]   [Full Text] [Related]  

  • 2. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Necchi A; Giardiello D; Mariani L
    Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
    [No Abstract]   [Full Text] [Related]  

  • 3. Atezolizumab (Tecentriq) for bladder cancer and NSCLC.
    Med Lett Drugs Ther; 2017 Feb; 59(1515):e40-e41. PubMed ID: 28222066
    [No Abstract]   [Full Text] [Related]  

  • 4. Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report.
    Bat T; Buck DA; Nathan R; Cinquino J; Sikorski M; Elefante A; Herbst L; Sule N; Fabiano A; George S
    Urology; 2019 Sep; 131():24-26. PubMed ID: 31059726
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.
    Yu SS; Dorff TB; Ballas LK; Sadeghi S; Skinner EC; Quinn DI
    Clin Adv Hematol Oncol; 2017 Jun; 15(6):466-477. PubMed ID: 28749907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTLA-4 Blockade Resistance after Relatlimab and Nivolumab.
    Menzies AM; Pires da Silva I; Trojaniello C; Vieu E; Amaria RN; Zimmer L; Lo SN; Burton EM; Tawbi HA; Schadendorf D; Grob JJ; Ascierto PA; Long GV
    N Engl J Med; 2022 Apr; 386(17):1668-1669. PubMed ID: 35476655
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Catalano M; Santoni M; Roviello G
    Eur Urol; 2024 Sep; 86(3):283. PubMed ID: 38744633
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Chen DC; AlSaffar H; Graefen H; Perera S; Mazzone E; Perera ML; Lawrentschuk N; Murphy DG
    Eur Urol; 2024 Sep; 86(3):282-283. PubMed ID: 38631993
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Klümper N; Vera-Badillo FE; Eckstein M; Hadaschik B; Grünwald V
    Eur Urol; 2024 Sep; 86(3):280-281. PubMed ID: 38599990
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
    Rassy EE; Bakouny Z; Aoun F; Haddad FG; Sleilaty G; Assi T; Kattan J
    Immunotherapy; 2018 Jun; 10(8):657-663. PubMed ID: 29562804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treating metastatic melanoma: Risk management].
    Lebbe C; Robert C
    Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
    [No Abstract]   [Full Text] [Related]  

  • 13. Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.
    Chang E; Sabichi AL; Sada YH
    J Immunother; 2017 Apr; 40(3):114-116. PubMed ID: 28234667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab associated hemophagocytic lymphohistiocytosis.
    Shah D; Shrestha R; Ramlal R; Hatton J; Saeed H
    Ann Oncol; 2017 Jun; 28(6):1403. PubMed ID: 28368439
    [No Abstract]   [Full Text] [Related]  

  • 15. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy in urothelial carcinoma from a pathologist's perspective].
    Erlmeier F; Steffens S; Hartmann A
    Aktuelle Urol; 2017 Aug; 48(4):336-339. PubMed ID: 28614852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant pembrolizumab in bladder cancer.
    Gourd E
    Lancet Oncol; 2018 Dec; 19(12):e669. PubMed ID: 30509883
    [No Abstract]   [Full Text] [Related]  

  • 18. A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval.
    Zameer U; Shaikh W
    Tumori; 2024 Aug; 110(4):295-296. PubMed ID: 38142292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
    Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
    Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune checkpoint inhibitors: a new frontier in bladder cancer.
    Kates M; Sopko NA; Matsui H; Drake CG; Hahn NM; Bivalacqua TJ
    World J Urol; 2016 Jan; 34(1):49-55. PubMed ID: 26487055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.